Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IIIA or IIIB disease~* Must be a candidate for curative radiotherapy~* Not a candidate for other concurrent chemotherapy and radiotherapy~* No surgical treatment available~* No pleural effusion suspected or proven to be malignant~* No stage IV disease by bone scan or positron emission tomography scan, CT scan or MRI of the brain, and CT scan of the chest within the past 30 days~PATIENT CHARACTERISTICS:~Age \* 18 and over~Performance status~* Eastern Cooperative Oncology Group (ECOG) 0-2 (age ≥ 65 years)~* ECOG 2 (age 18 to 64 years)~Life expectancy~\* At least 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~Renal~* Creatinine ≤ 1.5 times ULN~Pulmonary~* FEV_1 ≥ 1 L~* No idiopathic pulmonary fibrosis~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Magnesium normal~* No uncontrolled infection~* No other severe underlying disease that would preclude study entry~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma~* No major psychiatric illness that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~\* Not specified~Chemotherapy~* See Disease Characteristics~* No prior chemotherapy for NSCLC~Endocrine therapy~\* Not specified~Radiotherapy~* No prior therapeutic radiotherapy to the chest~* No concurrent intensity modulated radiotherapy~Other~\* No prior epidermal growth factor receptor inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab/Radiation (Type: EXPERIMENTAL): Cetuximab (C225) and Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).